Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Infosys Limited (INFY) vs Mesoblast Limited (MESO) Price & Performance

Infosys LimitedTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Infosys Limited vs Mesoblast Limited — how do they compare? Infosys Limited trades at $12.4 (market cap $50.32B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Infosys Limited is far larger — about 23.3× Mesoblast Limited's market cap, and Infosys Limited pays a 4.17% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.

INFYMESO
Market Cap
$50.32B$2.16B
Sector
TechnologyTechnology
52-Week High
$20.22$20.96
52-Week Low
$10.49$12.88
Enterprise Value
$48.07B$2.17B
Dividend Yield
4.17%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Infosys Limited

INFY trades at $12.53, up 1.38% today, with a bullish technical signal from moving averages. The company reported a Q1 2027 revenue miss but maintained strong operating margins of 21.1% and announced a CEO transition. Recent news highlights strategic AI collaborations, such as with Metsä Group and Sentara, driving digital transformation initiatives.

The outlook is mixed: robust profitability and AI growth offer upside, but lowered revenue guidance and competitive pressures pose risks. Analyst consensus is cautious with a $11.05 price target below the current price, suggesting limited near-term upside amid execution challenges.

Mesoblast Limited

MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.

Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.

Returns comparison

Trailing returns across standard periods

About Infosys Limited

Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.

Read more on INFY

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO